lomustine has been researched along with Glial Cell Tumors in 174 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Following maximal surgical resection, newly diagnosed children with nonmetastatic high-grade glioma underwent involved field radiotherapy with concurrent temozolomide." | 9.22 | Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study. ( Brat, DJ; Burger, PC; Buxton, A; Cohen, KJ; Eckel, SP; Hamilton, RL; Jakacki, RI; Krailo, MD; Lavey, RS; Pollack, IF; Rosenblum, MK; Zhou, T, 2016) |
| "A prior Radiation Therapy Oncology Group (RTOG) clinical trial in anaplastic oligodendroglioma suggested a progression-free survival benefit for procarbazine, lomustine, and vincristine (PCV) chemotherapy in addition to radiation therapy (RT), as have smaller trials in low-grade glioma (LGG)." | 9.16 | Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. ( Barger, GR; Brachman, DG; Brown, PD; Buckner, JC; Coons, SW; Gilbert, MR; Mehta, MP; Shaw, EG; Stelzer, KJ; Wang, M, 2012) |
| "Temozolomide (TMZ) is an alkylating agent licensed for treatment of high-grade glioma (HGG)." | 9.14 | Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. ( Beall, S; Brada, M; Collins, VP; Erridge, S; Gabe, R; Gattamaneni, R; Hopkins, K; Lee, SM; Levy, D; Rampling, R; Saran, F; Stenning, S; Thompson, LC, 2010) |
| "A phase I trial was conducted to determine the maximum tolerated dose (MTD) of temozolomide given in combination with lomustine in newly diagnosed pediatric patients with high-grade gliomas." | 9.13 | A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood. ( Adamson, PC; Blaney, SM; Flom, L; Ingle, AM; Jakacki, RI; Pollack, IF; Prados, MD; Timmerman, R; Yates, A; Zhou, T, 2008) |
| "The regimen of procarbazine, CCNU, and vincristine is active against gliomas." | 9.08 | Dose-intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas. ( Cornetta, K; Dropcho, E; Heilman, DK; Jakacki, RI; Jamison, C; Macdonald, DR; Mathews, VP; Williams, DA, 1998) |
| " The protocol called for a randomized trial that compared the effects of following 60 Gy radiation/oral hydroxyurea treatment with either carmustine (BCNU) or the combination of procarbazine, lomustine (CCNU), and vincristine (PCV) for two histologic strata: glioblastoma multiforme and other anaplastic gliomas." | 9.06 | Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. ( Davis, RL; Gutin, PH; Hannigan, J; Levin, VA; Silver, P; Wara, WM; Wilson, CB, 1990) |
| "The majority of patients with high-risk lower grade gliomas (LGG) are treated with single-agent temozolomide (TMZ) and radiotherapy despite three randomized trials showing a striking overall survival benefit with adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy and radiotherapy." | 9.05 | Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV. ( Atkins, KM; Dietrich, J; Loeffler, JS; McDuff, SGR; Oh, KS; Shih, HA, 2020) |
| "The authors report the results of a randomized study conducted to evaluate the relative benefit of treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or the combination of procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, and vincristine (PCV) administered after radiation therapy with hydroxyurea to 76 evaluable patients with glioblastoma multiforme and 72 patients with other anaplastic gliomas." | 9.05 | Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. ( Davis, RL; Gutin, PH; Levin, VA; Nutik, S; Resser, KJ; Vestnys, P; Wara, WM; Wilson, CB; Yatsko, K, 1985) |
| "To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma." | 8.95 | Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017) |
| "The methylhydrazine derivative Procarbazine (PCZ) as monotherapy or in combination with CCNU and vincristine (PCV) was evaluated in a vast number of clinical trials and is still used in patients with high-grade and low-grade gliomas." | 8.84 | Procarbazine--a traditional drug in the treatment of malignant gliomas. ( Bogdahn, U; Goerne, R; Hau, P, 2008) |
| "We evaluated O-(2-[18F]fluoroethyl)-l-tyrosine (FET) PET and MRI for early response assessment in recurrent glioma patients treated with lomustine-based chemotherapy." | 8.31 | Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET. ( Bauer, EK; Ceccon, GS; Fink, GR; Galldiks, N; Goldbrunner, R; Kabbasch, C; Langen, KJ; Lohmann, P; Stoffels, G; Tscherpel, C; Werner, JM; Wollring, MM, 2023) |
| "To investigate if triple combination of lomustine, temozolomide and irradiation reduces canine glioma cell survival in vitro." | 8.31 | Triple combination of lomustine, temozolomide and irradiation reduces canine glioma cell survival in vitro. ( Fuchs, D; Morandi, L; Nytko, KJ; Rohrer Bley, C; Tonon, C; Weyland, MS, 2023) |
| "Following optimal local therapy, adjuvant Procarbazine, Lomustine and Vincristine (PCV) improves overall survival (OS) in low-grade glioma (LGG)." | 8.02 | One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre. ( Aslam, R; Breathnach, OS; Coyne, Z; Grogan, L; Hennessy, BT; Hennessy, MA; Keogh, RJ; Morris, PG, 2021) |
| "Evidently, the conclusion of this study will provide an assessment on whether combined procarbazine, lomustine, and vincristine provides an effective and safe form of treatment for recurrent high-grade glioma." | 7.96 | A comparative study of the effectiveness and safety of combined procarbazine, lomustine, and vincristine as a therapeutic method for recurrent high-grade glioma: A protocol for systematic review and meta-analysis. ( Cai, Y; Jiang, YG; Jiang, ZH; Tan, ZG; Wang, M, 2020) |
| " The validated method has been successfully applied to a pharmacokinetic study of thermosensitive liposome-encapsulated lomustine containing iohexol and lomustine solution after intravenous administration to C6 glioma rats." | 7.77 | HPLC method validation for the quantification of lomustine to study pharmacokinetics of thermosensitive liposome-encapsulated lomustine containing iohexol for CT imaging in C6 glioma rats. ( Derendorf, H; Gao, J; Li, M; Liu, C; Yu, F; Zeng, Y; Zhang, B; Zhuang, L, 2011) |
| "To re-evaluate the cost effectiveness and median overall survival (OS) achieved in patients with recurrent malignant gliomas treated with temozolomide in British Columbia, as compared to previous lomustine use in the same patient population based on updated outcomes data." | 7.73 | Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia. ( Mabasa, VH; Taylor, SC, 2006) |
| " Here, we examined the effects of 3-aminobenzamide, a poly(ADP-ribose) polymerase inhibitor, on the chemosensitivity of human malignant glioma cells." | 7.70 | Poly(ADP-ribose) polymerase-independent potentiation of nitrosourea cytotoxicity by 3-aminobenzamide in human malignant glioma cells. ( Weller, M; Winter, S, 2000) |
| "The aim of this study was to evaluate the toxicity, response, and survival of patients with relapsed high-grade gliomas after radiation therapy (RT) combined with lomustine (CCNU)." | 7.70 | Reirradiation and lomustine in patients with relapsed high-grade gliomas. ( Arcicasa, M; Bidoli, E; Dedkov, A; Gigante, M; Roncadin, M; Trovò, MG, 1999) |
| "Our results indicate that chemotherapy with a combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea is active for patients with recurrent anaplastic gliomas and glioblastomas not previously treated with nitrosourea-based chemotherapy but is inactive for patients with glioblastomas previously treated with chemotherapy." | 7.69 | Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. ( Bruner, J; Flowers, A; Gleason, MJ; Ictech, SE; Jaeckle, KA; Kyritsis, AP; Levin, VA; Yung, WK, 1996) |
| "Effective chemotherapy using PCV (procarbazine, lomustine and vincristine) has been documented in anaplastic oligodendrogliomas and oligoastrocytomas." | 7.69 | [Assessment of procarbazine, vincristine and lomustine association (PCV protocol) in oligodendroglioma and mixed glioma]. ( Bouffet, E; Bret, P; Helfre, S; Jouvet, A; Mertens, P; Mornex, F; Sindou, M; Thiesse, P, 1997) |
| "Twenty-eight evaluable children with the diagnosis of brain stem glioma were treated with 5-fluorouracil and CCNU before posterior fossa irradiation (5500 rads); during irradiation, the children received hydroxyurea and misonidazole." | 7.67 | 5-Fluorouracil and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) followed by hydroxyurea, misonidazole, and irradiation for brain stem gliomas: a pilot study of the Brain Tumor Research Center and the Childrens Cancer Group. ( Allen, J; Edwards, MS; Levin, VA; Ortega, J; Vestnys, P; Wara, WM, 1984) |
| "Twenty-one patients with recurrent malignant central nervous system gliomas were treated with a combination of 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine." | 7.67 | Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine. ( Edwards, MS; Fulton, D; Levin, V; Prados, M; Rodriguez, LA; Silver, P, 1988) |
| "Intrinsic subtypes are highly prognostic in EORTC 26951 and improve outcome prediction when combined with other prognostic factors." | 6.78 | Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC stu ( de Rooi, J; den Dunnen, WF; Eilers, PH; Erdem-Eraslan, L; French, PJ; Gorlia, T; Gravendeel, LA; Idbaih, A; Kros, JM; Sillevis Smitt, PA; Spliet, WG; Teepen, JL; van den Bent, MJ; Wesseling, P, 2013) |
| "Effective treatment of glioma still stands as a challenge in medical science." | 5.62 | Lomustine Incorporated Lipid Nanostructures Demonstrated Preferential Anticancer Properties in C6 Glioma Cell Lines with Enhanced Pharmacokinetic Profile in Mice. ( Barik, B; Kumar, LA; Pattnaik, G; Satapathy, BS, 2021) |
| "Intracranial gliomas are a common malignancy in dogs, and are associated with a poor prognosis due to their aggressive nature and a lack of clinically effective treatments." | 5.48 | Survival times in dogs with presumptive intracranial gliomas treated with oral lomustine: A comparative retrospective study (2008-2017). ( Cohen, PW; Dewey, CW; Moirano, SJ; Wright, KZ, 2018) |
| "CCNU was used to treat human glioma cell line BT-325 with different concentration of cytokines or NO donors, NO levels was measured by Griess assay and cell survival was evaluated by MTT assay." | 5.32 | [Suppression of nitric oxide on cytotoxicity of Lomustine in glioma cell line BT- 325]. ( Chen, ZL; Gao, RL, 2003) |
| "Following maximal surgical resection, newly diagnosed children with nonmetastatic high-grade glioma underwent involved field radiotherapy with concurrent temozolomide." | 5.22 | Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study. ( Brat, DJ; Burger, PC; Buxton, A; Cohen, KJ; Eckel, SP; Hamilton, RL; Jakacki, RI; Krailo, MD; Lavey, RS; Pollack, IF; Rosenblum, MK; Zhou, T, 2016) |
| "The purpose of this prospective phase II/III trial was to study the effect of therapy intensification when combining procarbazine, lomustine, and vincristine (PCV) chemotherapy with a standard course of radiation therapy (RT) on cognitive functioning for patients with World Health Organization grade 2 low-grade gliomas (LGGs)." | 5.19 | Patients with primary brain tumors. ( Behrend, SW, 2014) |
| "The addition of PCV (procarbazine, lomustine, and vincristine) chemotherapy to radiotherapy (RT) for patients with WHO grade 2 glioma improves progression-free survival (PFS)." | 5.19 | Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02. ( Barger, GR; Brachman, DG; Brown, PD; Buckner, JC; Gilbert, MR; Hu, C; Mehta, MP; Prabhu, RS; Shaw, EG; Stelzer, KJ; Won, M, 2014) |
| "We evaluated the prognostic and predictive value of a range of molecular changes in the setting of a randomised trial comparing standard PCV (procarbazine, CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea) and vincristine) chemotherapy with the standard temozolomide (TMZ) 5-day (200 mg/m2/day) schedule and a 21-day (100 mg/m2/day) schedule in chemo-naïve, high-grade glioma (non-oligodendroglial tumours; WHO (World Health Organisation) grades III and IV) patients at first progression following radiotherapy." | 5.19 | Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial. ( Brada, M; Chan, R; Collins, VP; Di, Y; Gabe, R; Ichimura, K; Pearson, D; Stenning, SP; Thompson, LC, 2014) |
| "A prior Radiation Therapy Oncology Group (RTOG) clinical trial in anaplastic oligodendroglioma suggested a progression-free survival benefit for procarbazine, lomustine, and vincristine (PCV) chemotherapy in addition to radiation therapy (RT), as have smaller trials in low-grade glioma (LGG)." | 5.16 | Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. ( Barger, GR; Brachman, DG; Brown, PD; Buckner, JC; Coons, SW; Gilbert, MR; Mehta, MP; Shaw, EG; Stelzer, KJ; Wang, M, 2012) |
| "Temozolomide (TMZ) is an alkylating agent licensed for treatment of high-grade glioma (HGG)." | 5.14 | Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. ( Beall, S; Brada, M; Collins, VP; Erridge, S; Gabe, R; Gattamaneni, R; Hopkins, K; Lee, SM; Levy, D; Rampling, R; Saran, F; Stenning, S; Thompson, LC, 2010) |
| "A phase I trial was conducted to determine the maximum tolerated dose (MTD) of temozolomide given in combination with lomustine in newly diagnosed pediatric patients with high-grade gliomas." | 5.13 | A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood. ( Adamson, PC; Blaney, SM; Flom, L; Ingle, AM; Jakacki, RI; Pollack, IF; Prados, MD; Timmerman, R; Yates, A; Zhou, T, 2008) |
| "The aim of this study was to compare tolerance of a nitrosurea-based regime with 'standard' therapy of vincristine (VCR) and carboplatin for low-grade gliomas." | 5.10 | Tolerance of nitrosurea-based multiagent chemotherapy regime for low-grade pediatric gliomas. ( Hoddes, JA; Lancaster, DL; Michalski, A, 2003) |
| "The regimen of procarbazine, CCNU, and vincristine is active against gliomas." | 5.08 | Dose-intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas. ( Cornetta, K; Dropcho, E; Heilman, DK; Jakacki, RI; Jamison, C; Macdonald, DR; Mathews, VP; Williams, DA, 1998) |
| " The protocol called for a randomized trial that compared the effects of following 60 Gy radiation/oral hydroxyurea treatment with either carmustine (BCNU) or the combination of procarbazine, lomustine (CCNU), and vincristine (PCV) for two histologic strata: glioblastoma multiforme and other anaplastic gliomas." | 5.06 | Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. ( Davis, RL; Gutin, PH; Hannigan, J; Levin, VA; Silver, P; Wara, WM; Wilson, CB, 1990) |
| "The authors report the results of a randomized study conducted to evaluate the relative benefit of treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or the combination of procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, and vincristine (PCV) administered after radiation therapy with hydroxyurea to 76 evaluable patients with glioblastoma multiforme and 72 patients with other anaplastic gliomas." | 5.05 | Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. ( Davis, RL; Gutin, PH; Levin, VA; Nutik, S; Resser, KJ; Vestnys, P; Wara, WM; Wilson, CB; Yatsko, K, 1985) |
| "The majority of patients with high-risk lower grade gliomas (LGG) are treated with single-agent temozolomide (TMZ) and radiotherapy despite three randomized trials showing a striking overall survival benefit with adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy and radiotherapy." | 5.05 | Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV. ( Atkins, KM; Dietrich, J; Loeffler, JS; McDuff, SGR; Oh, KS; Shih, HA, 2020) |
| "A controlled study of 226 age-matched patients with histologically proven grade 3 and 4 supratentorial gliomas with maximum feasible tumour resection, postoperative Karnofsky performance over 50 and minimum survival of 8 weeks compares the results of supportive care (45 cases), high-dose irradiation of 40 to 66 Gy (59 cases), COMP protocol (CCNU, procarbazine, vincristine, methotrexate, prednisone in 15 day cycles-42 cases) and simultaneous irradiation and COMP chemotherapy (80 cases including 30 survivors)." | 5.05 | [Combined treatment of malignant gliomas]. ( Flament, H; Grisold, W; Jellinger, K; Volc, D; Vollmer, R; Weiss, R, 1983) |
| "Forty-three patients with inoperable and/or recurring malignant gliomas, and 30 patients with multiple recurring brain metastases were treated with a combination of adriamycine (45 mg/m2) and 4-dimethyl-epipodophyllotoxin D-thenylidene (VM 26) (60 mg/m2 for 2 days) with 1-(2-chloroethyl) -3-cyclohexyl-1-nitroso-urea (CCNU) (60 mg/m2 for two days)." | 5.04 | [Trial treatment of glioblastomas in adults and cerebral metastais by adriamycin, VM 26 and CCNU combination. Result of a type II trial]. ( Buge, A; Gautier, H; Huguenin, P; Lheritier, J; Mathé, G; Morin, P; Parrot, R; Poisson, M; Pouillart, P; Thy, HT, 1976) |
| "Forty-three patients with inoperable and/or recurring malignant gliomas and 30 patients with multiple recurring brain metastases were treated with a combination of adriamycine (45 mg/m 2 and 4-dimethyl-epipodophyllotoxin D-thenylidene (VM 26) (60 mg/m 2 for 2 days) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-urea (CCNU) (60 mg/m 2 for 2 days)." | 5.04 | Treatment of malignant gliomas and brain metastases in adults using a combination of adriamycine, VM 26, and CCNU. Results of a type II trial. ( Gautier, H; Huguenin, P; Lheritier, J; Mathé, G; Morin, P; Palangie, T; Parrot, R; Poisson, M; Pouillart, P, 1977) |
| "To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma." | 4.95 | Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017) |
| "The long-term follow-up of the RTOG 9802 trial that compared 54 Gy of radiotherapy (RT) with the same RT followed by adjuvant procarbazine, CCNU, and vincristine (PCV) chemotherapy in high-risk low-grade glioma shows a major increase in survival after adjuvant PCV chemotherapy." | 4.90 | Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma. ( van den Bent, MJ, 2014) |
| "The methylhydrazine derivative Procarbazine (PCZ) as monotherapy or in combination with CCNU and vincristine (PCV) was evaluated in a vast number of clinical trials and is still used in patients with high-grade and low-grade gliomas." | 4.84 | Procarbazine--a traditional drug in the treatment of malignant gliomas. ( Bogdahn, U; Goerne, R; Hau, P, 2008) |
| "We report two patients with acute myeloid leukemia (AML) following therapy for malignant glioma; one was a young women treated heavily with alkylating agents for glioblastoma and the other a young man treated with high doses of procarbazine, lomustine, and vincristine (PCV) for anaplastic astrocytoma." | 4.80 | Acute leukemia following treatment of malignant glioma. ( Brown, MT; Gockerman, JP; Perry, JR, 1998) |
| "To investigate if triple combination of lomustine, temozolomide and irradiation reduces canine glioma cell survival in vitro." | 4.31 | Triple combination of lomustine, temozolomide and irradiation reduces canine glioma cell survival in vitro. ( Fuchs, D; Morandi, L; Nytko, KJ; Rohrer Bley, C; Tonon, C; Weyland, MS, 2023) |
| "We evaluated O-(2-[18F]fluoroethyl)-l-tyrosine (FET) PET and MRI for early response assessment in recurrent glioma patients treated with lomustine-based chemotherapy." | 4.31 | Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET. ( Bauer, EK; Ceccon, GS; Fink, GR; Galldiks, N; Goldbrunner, R; Kabbasch, C; Langen, KJ; Lohmann, P; Stoffels, G; Tscherpel, C; Werner, JM; Wollring, MM, 2023) |
| "Following optimal local therapy, adjuvant Procarbazine, Lomustine and Vincristine (PCV) improves overall survival (OS) in low-grade glioma (LGG)." | 4.02 | One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre. ( Aslam, R; Breathnach, OS; Coyne, Z; Grogan, L; Hennessy, BT; Hennessy, MA; Keogh, RJ; Morris, PG, 2021) |
| "Evidently, the conclusion of this study will provide an assessment on whether combined procarbazine, lomustine, and vincristine provides an effective and safe form of treatment for recurrent high-grade glioma." | 3.96 | A comparative study of the effectiveness and safety of combined procarbazine, lomustine, and vincristine as a therapeutic method for recurrent high-grade glioma: A protocol for systematic review and meta-analysis. ( Cai, Y; Jiang, YG; Jiang, ZH; Tan, ZG; Wang, M, 2020) |
| "The addition of procarbazine, lomustine, vincristine (PCV) chemotherapy to radiotherapy (RT) for patients with high-risk (≥40 y old or subtotally resected) low-grade glioma (LGG) results in an absolute median survival benefit of over 5 years." | 3.85 | Cost-effectiveness of radiation and chemotherapy for high-risk low-grade glioma. ( Bendavid, E; Chang, DT; Chin, AL; Durkee, BY; Harris, JP; Kim, H; Kumar, KA; Maruyama, S; Owens, DK; Pitt, A; Pollom, EL; Qian, Y; Soltys, SG, 2017) |
| "We previously developed a mathematical model capturing tumor size dynamics of adult low-grade gliomas (LGGs) before and after treatment either with PCV (Procarbazine, CCNU, and Vincristine) chemotherapy alone or with radiotherapy (RT) alone." | 3.81 | Increasing the Time Interval between PCV Chemotherapy Cycles as a Strategy to Improve Duration of Response in Low-Grade Gliomas: Results from a Model-Based Clinical Trial Simulation. ( Ducray, F; Honnorat, J; Mazzocco, P; Ribba, B, 2015) |
| "Sixty-four patients who received at least one cycle of a nitrosourea agent (nimustine or lomustine) and teniposide for recurrent glioma between 2008 and 2012; of these patients, 28 did not receive prophylactic pegfilgrastim (cohort A), and 36 patients received prophylactic pegfilgrastim (cohort B)." | 3.80 | Prophylactic use of pegfilgrastim in patients treated with a nitrosourea and teniposide for recurrent glioma. ( Atta, J; Franz, K; Lemercier, S; Rieger, J; Steinbach, JP; Sulzbacher, A; Thiepold, AL, 2014) |
| " The validated method has been successfully applied to a pharmacokinetic study of thermosensitive liposome-encapsulated lomustine containing iohexol and lomustine solution after intravenous administration to C6 glioma rats." | 3.77 | HPLC method validation for the quantification of lomustine to study pharmacokinetics of thermosensitive liposome-encapsulated lomustine containing iohexol for CT imaging in C6 glioma rats. ( Derendorf, H; Gao, J; Li, M; Liu, C; Yu, F; Zeng, Y; Zhang, B; Zhuang, L, 2011) |
| "To re-evaluate the cost effectiveness and median overall survival (OS) achieved in patients with recurrent malignant gliomas treated with temozolomide in British Columbia, as compared to previous lomustine use in the same patient population based on updated outcomes data." | 3.73 | Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia. ( Mabasa, VH; Taylor, SC, 2006) |
| "Carmustine and lomustine are nitrosourea antitumor chemotherapeutic agents which were used to determine whether or not they could affect arylamine N-acetyltransferase (NAT) activity and DNA-2-aminofluorene adducts in rat glial tumor cell line (C6 glioma)." | 3.70 | Effects of carmustine and lomustine on arylamine N-acetyltransferase activity and 2-aminofluorene-DNA adducts in rat glial tumor cells. ( Hung, CF, 2000) |
| "The aim of this study was to evaluate the toxicity, response, and survival of patients with relapsed high-grade gliomas after radiation therapy (RT) combined with lomustine (CCNU)." | 3.70 | Reirradiation and lomustine in patients with relapsed high-grade gliomas. ( Arcicasa, M; Bidoli, E; Dedkov, A; Gigante, M; Roncadin, M; Trovò, MG, 1999) |
| " Here, we examined the effects of 3-aminobenzamide, a poly(ADP-ribose) polymerase inhibitor, on the chemosensitivity of human malignant glioma cells." | 3.70 | Poly(ADP-ribose) polymerase-independent potentiation of nitrosourea cytotoxicity by 3-aminobenzamide in human malignant glioma cells. ( Weller, M; Winter, S, 2000) |
| "Our results indicate that chemotherapy with a combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea is active for patients with recurrent anaplastic gliomas and glioblastomas not previously treated with nitrosourea-based chemotherapy but is inactive for patients with glioblastomas previously treated with chemotherapy." | 3.69 | Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. ( Bruner, J; Flowers, A; Gleason, MJ; Ictech, SE; Jaeckle, KA; Kyritsis, AP; Levin, VA; Yung, WK, 1996) |
| "Effective chemotherapy using PCV (procarbazine, lomustine and vincristine) has been documented in anaplastic oligodendrogliomas and oligoastrocytomas." | 3.69 | [Assessment of procarbazine, vincristine and lomustine association (PCV protocol) in oligodendroglioma and mixed glioma]. ( Bouffet, E; Bret, P; Helfre, S; Jouvet, A; Mertens, P; Mornex, F; Sindou, M; Thiesse, P, 1997) |
| "Twenty-eight evaluable children with the diagnosis of brain stem glioma were treated with 5-fluorouracil and CCNU before posterior fossa irradiation (5500 rads); during irradiation, the children received hydroxyurea and misonidazole." | 3.67 | 5-Fluorouracil and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) followed by hydroxyurea, misonidazole, and irradiation for brain stem gliomas: a pilot study of the Brain Tumor Research Center and the Childrens Cancer Group. ( Allen, J; Edwards, MS; Levin, VA; Ortega, J; Vestnys, P; Wara, WM, 1984) |
| "One hundred and seventeen patients with cerebral glioma (Kernohan grades III and IV) were treated with adjuvant chemotherapy using procarbazine (PCB), CCNU and vincristine (VCR) following whole head irradiation." | 3.67 | Assay of anti-cancer drugs in tissue culture: relationship of relapse free interval (RFI) and in vitro chemosensitivity in patients with malignant cerebral glioma. ( Bozek, T; Capra, LG; Collins, CD; Darling, JL; Godlee, JN; Mooney, C; Mott, TJ; Paul, EA; Thomas, DG; Tobias, JS, 1985) |
| "Twenty-one patients with recurrent malignant central nervous system gliomas were treated with a combination of 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine." | 3.67 | Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine. ( Edwards, MS; Fulton, D; Levin, V; Prados, M; Rodriguez, LA; Silver, P, 1988) |
| "A patient with a mixed malignant glioma metastatic to the bones and lungs failed to respond to two different broad-spectrum combination chemotherapy regimens which included Adriamycin, methotrexate, cyclophosphamide, CCNU and cis-dichlorodiammineplatinum(II)." | 3.66 | Combination chemotherapy for extracranial metastases of a primary malignant cerebral neoplasm. ( Oster, MW, 1979) |
| "Intracerebral murine glioma 26 was used as a model system for evaluating two-drug combinations of antitumor agents, BCNU was combined with either procarbazine, dianhydrogalactitol, or ellipticine." | 3.66 | Correlations between experimental chemotherapy in the murine glioma and effectiveness of clinical therapy regimens. ( Levin, VA; Wilson, CB, 1978) |
| "Forty-three patients with inoperable or recurring malignant gliomas, and 30 patients with multiple recurring brain metastases were treated with a combination of Adriamycin (45 mg/m2) and 4-dimethyl-epipodophyllotoxin D-thenylidene (VM 26) (60 mg/m2 for 2 days) with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (60 mg/m2 for 2 days)." | 3.65 | Treatment of malignant gliomas and brain metastases in adults with a combination of adriamycin, VM 26, and CCNU. Results of a phase II trail. ( Gauthier, H; Huguenin, P; Lheritier, J; Mathe, G; Morin, P; Parrot, R; Poisson, M; Pouillart, P; Thy, TH, 1976) |
| "Intrinsic subtypes are highly prognostic in EORTC 26951 and improve outcome prediction when combined with other prognostic factors." | 2.78 | Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC stu ( de Rooi, J; den Dunnen, WF; Eilers, PH; Erdem-Eraslan, L; French, PJ; Gorlia, T; Gravendeel, LA; Idbaih, A; Kros, JM; Sillevis Smitt, PA; Spliet, WG; Teepen, JL; van den Bent, MJ; Wesseling, P, 2013) |
| "Those treated for glioblastoma multiforme had a mean Karnofsky Performance Score of 86% (range 60-100%) at 1 month and 75% (range 60-100%) at 24 months." | 2.67 | External irradiation followed by an interstitial high activity iodine-125 implant "boost" in the initial treatment of malignant gliomas: NCOG study 6G-82-2. ( Gutin, PH; Larson, DA; Leibel, SA; Levin, VA; Phillips, TL; Prados, MD; Silver, P; Sneed, PK; Wara, WM; Weaver, KA, 1991) |
| " Nor did the analysis of life quality and of changes in clinical performance show any benefit in supplementing surgery and radiation therapy with CCNU chemotherapy at the dosage used." | 2.66 | Quality of survival of patients with brain gliomas treated with postoperative CCNU and radiation therapy. ( Bendarzewska, B; Bielawski, A; Dabrowska, A; Gościński, I; Lopatkiewicz, J; Markiewicz, P; Peszyński, J; Szymona, J; Trojanowski, T; Turowski, K, 1989) |
| " On the other side, dosage and the interval between cycles of chemotherapy appear to be a determining factor in the activity, but the limits are very narrow." | 2.64 | [A study of the use of sequential chemotherapy in 176 cases of glioblastoma (author's transl)]. ( Buge, A; Poisson, M; Pouillart, P, 1978) |
| "Gliomas are the most frequent primary brain tumors." | 2.50 | [Management of gliomas]. ( Chapet, S; Lévy, S; Mazeron, JJ, 2014) |
| "Oligodendrogliomas were clearly defined as tumors with IDH mutations and 1p/19q codeletion by the World Health Organization(WHO)in 2016." | 1.91 | [Oligodendroglioma, IDH Mutation and 1p/19q Codeletion]. ( Matsutani, T, 2023) |
| "Effective treatment of glioma still stands as a challenge in medical science." | 1.62 | Lomustine Incorporated Lipid Nanostructures Demonstrated Preferential Anticancer Properties in C6 Glioma Cell Lines with Enhanced Pharmacokinetic Profile in Mice. ( Barik, B; Kumar, LA; Pattnaik, G; Satapathy, BS, 2021) |
| "Intracranial gliomas are a common malignancy in dogs, and are associated with a poor prognosis due to their aggressive nature and a lack of clinically effective treatments." | 1.48 | Survival times in dogs with presumptive intracranial gliomas treated with oral lomustine: A comparative retrospective study (2008-2017). ( Cohen, PW; Dewey, CW; Moirano, SJ; Wright, KZ, 2018) |
| "Malignant gliomas are the most common primary intrinsic brain tumors and are highly lethal." | 1.35 | Nitrosoureas inhibit the stathmin-mediated migration and invasion of malignant glioma cells. ( Choi, Y; Liang, XJ; Park, JK; Sackett, DL, 2008) |
| "CCNU was used to treat human glioma cell line BT-325 with different concentration of cytokines or NO donors, NO levels was measured by Griess assay and cell survival was evaluated by MTT assay." | 1.32 | [Suppression of nitric oxide on cytotoxicity of Lomustine in glioma cell line BT- 325]. ( Chen, ZL; Gao, RL, 2003) |
| "5 g/M2 every six weeks, with dosage adjustments for myelotoxicity." | 1.27 | Misonidazole and CCNU chemotherapy for recurrent primary brain tumor. ( Fulton, DS; McKinnon, S; Tanasichuk, H; Urtasun, RC, 1987) |
| "Bone marrow myelofibrosis may be another delayed treatment effect of this class of drugs." | 1.27 | Myelofibrosis following treatment with a nitrosourea for malignant glioma. ( Fehir, KM; McKenney, SA, 1986) |
| " The depression of platelets and white blood cells was mild after a single dosage of 40 mg/kg CCNU which recovered on about the 6th day." | 1.26 | Brain tumor chemotherapy using a rat glioma model. ( Mennel, HD; Tamura, M; Zülch, KJ, 1979) |
| "34 patients operated on for malignant gliomas were successively treated by combination chemotherapy with VM26 and CCNU and conventional radiation therapy with an average dosage of 5,800 Rads, six months after surgery." | 1.26 | Malignant gliomas treated after surgery by combination chemotherapy and delayed radiation therapy. Part II. Tolerance to irradiation after chemotherapy. ( Bataini, JP; Hauw, JJ; Mashaly, R; Metzger, J; Pertuiset, BF; Poisson, M; Pouillart, P, 1979) |
| " However, with certain dosage schedules such as every 2 hr for 5 injections daily on 2 consecutive days, i." | 1.26 | Chemotherapy of an experimental glioma with nitrosoureas. ( Day, A; Liberman, L; Ng, R; Tator, CH, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 78 (44.83) | 18.7374 |
| 1990's | 26 (14.94) | 18.2507 |
| 2000's | 28 (16.09) | 29.6817 |
| 2010's | 32 (18.39) | 24.3611 |
| 2020's | 10 (5.75) | 2.80 |
| Authors | Studies |
|---|---|
| Satapathy, BS | 1 |
| Kumar, LA | 1 |
| Pattnaik, G | 1 |
| Barik, B | 1 |
| Giotta Lucifero, A | 1 |
| Elbabaa, SK | 1 |
| Baldoncini, M | 1 |
| Bruno, N | 1 |
| Savasta, S | 1 |
| Marseglia, GL | 1 |
| Luzzi, S | 1 |
| Wollring, MM | 1 |
| Werner, JM | 1 |
| Bauer, EK | 1 |
| Tscherpel, C | 1 |
| Ceccon, GS | 1 |
| Lohmann, P | 1 |
| Stoffels, G | 1 |
| Kabbasch, C | 1 |
| Goldbrunner, R | 1 |
| Fink, GR | 1 |
| Langen, KJ | 1 |
| Galldiks, N | 1 |
| Fuchs, D | 1 |
| Rohrer Bley, C | 1 |
| Morandi, L | 1 |
| Tonon, C | 1 |
| Weyland, MS | 1 |
| Nytko, KJ | 1 |
| Matsutani, T | 1 |
| McDuff, SGR | 1 |
| Dietrich, J | 1 |
| Atkins, KM | 1 |
| Oh, KS | 1 |
| Loeffler, JS | 1 |
| Shih, HA | 1 |
| Raswoli, M | 1 |
| Nobre, L | 1 |
| Hawkins, C | 2 |
| Bartels, UK | 1 |
| Tabori, U | 2 |
| Bouffet, E | 3 |
| Cai, Y | 1 |
| Jiang, YG | 1 |
| Wang, M | 3 |
| Jiang, ZH | 1 |
| Tan, ZG | 1 |
| Cloughesy, TF | 1 |
| Petrecca, K | 1 |
| Walbert, T | 1 |
| Butowski, N | 1 |
| Salacz, M | 1 |
| Perry, J | 1 |
| Damek, D | 1 |
| Bota, D | 1 |
| Bettegowda, C | 1 |
| Zhu, JJ | 1 |
| Iwamoto, F | 1 |
| Placantonakis, D | 1 |
| Kim, L | 1 |
| Elder, B | 1 |
| Kaptain, G | 1 |
| Cachia, D | 1 |
| Moshel, Y | 1 |
| Brem, S | 2 |
| Piccioni, D | 1 |
| Landolfi, J | 1 |
| Chen, CC | 1 |
| Gruber, H | 1 |
| Rao, AR | 1 |
| Hogan, D | 1 |
| Accomando, W | 1 |
| Ostertag, D | 1 |
| Montellano, TT | 1 |
| Kheoh, T | 1 |
| Kabbinavar, F | 1 |
| Vogelbaum, MA | 1 |
| Keogh, RJ | 1 |
| Aslam, R | 1 |
| Hennessy, MA | 1 |
| Coyne, Z | 1 |
| Hennessy, BT | 1 |
| Breathnach, OS | 1 |
| Grogan, L | 1 |
| Morris, PG | 1 |
| Qian, Y | 1 |
| Maruyama, S | 1 |
| Kim, H | 1 |
| Pollom, EL | 1 |
| Kumar, KA | 1 |
| Chin, AL | 1 |
| Harris, JP | 1 |
| Chang, DT | 1 |
| Pitt, A | 1 |
| Bendavid, E | 1 |
| Owens, DK | 1 |
| Durkee, BY | 1 |
| Soltys, SG | 1 |
| Parasramka, S | 1 |
| Talari, G | 1 |
| Rosenfeld, M | 1 |
| Guo, J | 1 |
| Villano, JL | 1 |
| Wick, W | 2 |
| Winkler, F | 1 |
| Moirano, SJ | 1 |
| Dewey, CW | 1 |
| Wright, KZ | 1 |
| Cohen, PW | 1 |
| Stupp, R | 2 |
| Prabhu, RS | 1 |
| Won, M | 1 |
| Shaw, EG | 2 |
| Hu, C | 1 |
| Brachman, DG | 2 |
| Buckner, JC | 2 |
| Stelzer, KJ | 2 |
| Barger, GR | 2 |
| Brown, PD | 2 |
| Gilbert, MR | 2 |
| Mehta, MP | 3 |
| Kaloshi, G | 2 |
| Rroji, A | 2 |
| Petrela, M | 2 |
| Thiepold, AL | 1 |
| Lemercier, S | 1 |
| Franz, K | 1 |
| Atta, J | 1 |
| Sulzbacher, A | 1 |
| Steinbach, JP | 1 |
| Rieger, J | 1 |
| Behrend, SW | 1 |
| Collins, VP | 2 |
| Ichimura, K | 1 |
| Di, Y | 1 |
| Pearson, D | 1 |
| Chan, R | 1 |
| Thompson, LC | 2 |
| Gabe, R | 2 |
| Brada, M | 2 |
| Stenning, SP | 1 |
| Lévy, S | 1 |
| Chapet, S | 1 |
| Mazeron, JJ | 1 |
| van den Bent, MJ | 3 |
| Schiff, D | 1 |
| Levin, VA | 13 |
| Rinne, ML | 1 |
| Wen, PY | 1 |
| Roci, E | 1 |
| Ducray, F | 5 |
| Duerinck, J | 1 |
| Du Four, S | 1 |
| Sander, W | 1 |
| Van Binst, AM | 1 |
| Everaert, H | 1 |
| Michotte, A | 1 |
| Hau, P | 2 |
| Neyns, B | 1 |
| Brandes, AA | 1 |
| Bartolotti, M | 1 |
| Tosoni, A | 1 |
| Franceschi, E | 1 |
| Mazzocco, P | 1 |
| Honnorat, J | 2 |
| Ribba, B | 1 |
| Jakacki, RI | 4 |
| Cohen, KJ | 1 |
| Buxton, A | 1 |
| Krailo, MD | 1 |
| Burger, PC | 2 |
| Rosenblum, MK | 1 |
| Brat, DJ | 1 |
| Hamilton, RL | 1 |
| Eckel, SP | 1 |
| Zhou, T | 3 |
| Lavey, RS | 1 |
| Pollack, IF | 4 |
| Goerne, R | 1 |
| Bogdahn, U | 1 |
| Liang, XJ | 1 |
| Choi, Y | 1 |
| Sackett, DL | 1 |
| Park, JK | 1 |
| Ashley, DM | 1 |
| Riffkin, CD | 1 |
| Lovric, MM | 1 |
| Mikeska, T | 1 |
| Dobrovic, A | 1 |
| Maxwell, JA | 1 |
| Friedman, HS | 2 |
| Drummond, KJ | 1 |
| Kaye, AH | 1 |
| Gan, HK | 1 |
| Johns, TG | 1 |
| Hawkins, CJ | 1 |
| Baumert, BG | 1 |
| Amarasingh, S | 1 |
| Macleod, MR | 1 |
| Whittle, IR | 1 |
| DeAngelis, LM | 1 |
| Hartmann, C | 1 |
| Engel, C | 1 |
| Stoffels, M | 1 |
| Felsberg, J | 1 |
| Stockhammer, F | 1 |
| Sabel, MC | 1 |
| Koeppen, S | 1 |
| Ketter, R | 1 |
| Meyermann, R | 1 |
| Rapp, M | 1 |
| Meisner, C | 1 |
| Kortmann, RD | 1 |
| Pietsch, T | 1 |
| Wiestler, OD | 1 |
| Ernemann, U | 1 |
| Bamberg, M | 2 |
| Reifenberger, G | 1 |
| von Deimling, A | 1 |
| Weller, M | 3 |
| Mishra, KK | 1 |
| Squire, S | 1 |
| Lamborn, K | 3 |
| Banerjee, A | 1 |
| Gupta, N | 1 |
| Wara, WM | 6 |
| Prados, MD | 6 |
| Berger, MS | 1 |
| Haas-Kogan, DA | 1 |
| Agha, CA | 1 |
| Ibrahim, S | 1 |
| Hassan, A | 1 |
| Elias, DA | 1 |
| Fathallah-Shaykh, HM | 1 |
| Peyre, M | 1 |
| Cartalat-Carel, S | 1 |
| Meyronet, D | 1 |
| Ricard, D | 1 |
| Jouvet, A | 3 |
| Pallud, J | 1 |
| Mokhtari, K | 1 |
| Guyotat, J | 2 |
| Jouanneau, E | 2 |
| Sunyach, MP | 2 |
| Frappaz, D | 2 |
| Stenning, S | 1 |
| Levy, D | 1 |
| Rampling, R | 1 |
| Erridge, S | 1 |
| Saran, F | 1 |
| Gattamaneni, R | 1 |
| Hopkins, K | 1 |
| Beall, S | 1 |
| Lee, SM | 1 |
| Zhuang, L | 1 |
| Gao, J | 1 |
| Zeng, Y | 1 |
| Yu, F | 1 |
| Zhang, B | 1 |
| Li, M | 1 |
| Derendorf, H | 1 |
| Liu, C | 1 |
| Scheinemann, K | 1 |
| Bartels, U | 1 |
| Tsangaris, E | 1 |
| Huang, A | 1 |
| Dirks, P | 1 |
| Fried, I | 1 |
| Ater, JL | 1 |
| Holmes, E | 1 |
| Mazewski, CM | 1 |
| Booth, TN | 1 |
| Freyer, DR | 1 |
| Lazarus, KH | 1 |
| Packer, RJ | 2 |
| Prados, M | 3 |
| Sposto, R | 1 |
| Vezina, G | 1 |
| Wisoff, JH | 1 |
| Coons, SW | 1 |
| Viaccoz, A | 1 |
| Lekoubou, A | 1 |
| Dignam, JJ | 1 |
| Zhang, QE | 1 |
| DeGroot, JF | 1 |
| Hunsberger, S | 1 |
| Erdem-Eraslan, L | 1 |
| Gravendeel, LA | 1 |
| de Rooi, J | 1 |
| Eilers, PH | 1 |
| Idbaih, A | 1 |
| Spliet, WG | 1 |
| den Dunnen, WF | 1 |
| Teepen, JL | 1 |
| Wesseling, P | 1 |
| Sillevis Smitt, PA | 2 |
| Kros, JM | 1 |
| Gorlia, T | 1 |
| French, PJ | 1 |
| Baker, MJ | 1 |
| Daniels, S | 1 |
| Sherman, B | 1 |
| Phuphanich, S | 1 |
| Vos, MJ | 1 |
| Uitdehaag, BM | 1 |
| Barkhof, F | 1 |
| Heimans, JJ | 2 |
| Baayen, HC | 1 |
| Boogerd, W | 1 |
| Castelijns, JA | 1 |
| Elkhuizen, PH | 1 |
| Postma, TJ | 2 |
| Pommier, P | 1 |
| Martel Lafay, I | 1 |
| Ginestet, G | 1 |
| Sindou, M | 2 |
| Bret, P | 2 |
| Carrie, C | 1 |
| Lancaster, DL | 1 |
| Hoddes, JA | 1 |
| Michalski, A | 1 |
| Fouladi, M | 1 |
| Hunt, DL | 1 |
| Dueckers, G | 1 |
| Becker, LE | 1 |
| Yates, AJ | 1 |
| Gilles, FH | 1 |
| Davis, RL | 4 |
| Boyett, JM | 1 |
| Finlay, JL | 1 |
| Gao, RL | 1 |
| Chen, ZL | 1 |
| Pillai, A | 1 |
| Rajeev, K | 1 |
| Chandi, S | 1 |
| Unnikrishnan, M | 1 |
| de Wit, MC | 1 |
| de Bruin, HG | 1 |
| Eijkenboom, W | 1 |
| Tafuto, S | 1 |
| Muto, P | 1 |
| Tortoriello, A | 1 |
| Pisano, A | 1 |
| Comella, P | 1 |
| Formato, R | 1 |
| Quattrin, S | 1 |
| Iaffaioli, RV | 1 |
| Mabasa, VH | 1 |
| Taylor, SC | 1 |
| Yang, SH | 1 |
| Hong, YK | 1 |
| Yoon, SC | 1 |
| Kim, BS | 1 |
| Lee, YS | 1 |
| Lee, TK | 1 |
| Lee, KS | 1 |
| Jeun, SS | 1 |
| Kim, MC | 1 |
| Park, CK | 1 |
| Wolff, JE | 1 |
| Berrak, S | 1 |
| Koontz Webb, SE | 1 |
| Zhang, M | 1 |
| Choi, JD | 1 |
| Powers, CJ | 1 |
| Vredenburgh, JJ | 1 |
| Friedman, AH | 1 |
| Sampson, JH | 1 |
| Kobiakov, GL | 1 |
| Yates, A | 1 |
| Blaney, SM | 1 |
| Timmerman, R | 1 |
| Ingle, AM | 1 |
| Flom, L | 1 |
| Adamson, PC | 1 |
| Edwards, MS | 3 |
| Allen, J | 1 |
| Ortega, J | 1 |
| Vestnys, P | 2 |
| Kessinger, A | 1 |
| Jellinger, K | 3 |
| Volc, D | 3 |
| Grisold, W | 3 |
| Podreka, I | 2 |
| Böck, F | 1 |
| Schuster, H | 1 |
| Alth, G | 1 |
| Kogelnik, HD | 1 |
| Robustelli della Cuna, G | 1 |
| Paoletti, P | 5 |
| Bernardo, G | 1 |
| Knerich, R | 3 |
| Butti, G | 2 |
| Cuzzoni, Q | 1 |
| Barrere, M | 1 |
| Fanjaud, G | 1 |
| Larrue, V | 1 |
| Geraud, G | 1 |
| Bes, A | 1 |
| Jacque, C | 1 |
| Kujas, M | 1 |
| Raoul, M | 1 |
| Baumann, N | 1 |
| Poisson, M | 7 |
| Fingert, HJ | 1 |
| Hochberg, FH | 1 |
| Flament, H | 2 |
| Vollmer, R | 2 |
| Weiss, R | 2 |
| Shapiro, WR | 2 |
| Hildebrand, J | 2 |
| Badjou, R | 1 |
| Collard-Ronge, E | 1 |
| Delforge, A | 1 |
| Malarme, M | 1 |
| Spiro, T | 1 |
| Sztern, B | 1 |
| Vandensteene, A | 1 |
| Stryckmans, PA | 1 |
| Wilson, CB | 8 |
| Vestnys, PS | 1 |
| Muir, W | 1 |
| Chin, HW | 1 |
| Young, AB | 1 |
| Maruyama, Y | 1 |
| Ilsen, HW | 1 |
| Petrovici, IN | 1 |
| Mennel, HD | 3 |
| Zülch, KJ | 2 |
| Szymas, J | 1 |
| Huang, Q | 1 |
| Açikgöz, S | 1 |
| Bingol, F | 1 |
| offin, S | 1 |
| Açikgöz, B | 1 |
| Cairncross, JG | 2 |
| Eyre, HJ | 1 |
| Crowley, JJ | 1 |
| Townsend, JJ | 1 |
| Eltringham, JR | 1 |
| Morantz, RA | 1 |
| Schulman, SF | 1 |
| Quagliana, JM | 1 |
| al-Sarraf, M | 1 |
| Haselsberger, K | 1 |
| Peterson, DC | 1 |
| Thomas, DG | 4 |
| Darling, JL | 5 |
| Schlegel, J | 1 |
| Stumm, G | 1 |
| Ruschoff, J | 1 |
| Kyritsis, AP | 1 |
| Yung, WK | 1 |
| Jaeckle, KA | 1 |
| Bruner, J | 1 |
| Gleason, MJ | 1 |
| Ictech, SE | 1 |
| Flowers, A | 1 |
| Rabbitt, J | 2 |
| Hayat, K | 1 |
| Jones, B | 1 |
| Bisbrown, G | 1 |
| Baria, K | 1 |
| Pigott, T | 1 |
| El-Deredy, W | 1 |
| Ashmore, SM | 1 |
| Branston, NM | 1 |
| Williams, SR | 1 |
| Mornex, F | 1 |
| Thiesse, P | 1 |
| Mertens, P | 1 |
| Helfre, S | 1 |
| van Groeningen, CJ | 1 |
| Witjes, RJ | 1 |
| Weerts, JG | 1 |
| Kralendonk, JH | 1 |
| Urban, C | 1 |
| Benesch, M | 1 |
| Pakisch, B | 1 |
| Lackner, H | 1 |
| Kerbl, R | 1 |
| Schwinger, W | 1 |
| Oberbauer, R | 1 |
| Jamison, C | 2 |
| Mathews, VP | 1 |
| Heilman, DK | 1 |
| Dropcho, E | 1 |
| Cornetta, K | 1 |
| Macdonald, DR | 1 |
| Williams, DA | 1 |
| Perry, JR | 1 |
| Brown, MT | 1 |
| Gockerman, JP | 1 |
| Arcicasa, M | 1 |
| Roncadin, M | 1 |
| Bidoli, E | 1 |
| Dedkov, A | 1 |
| Gigante, M | 1 |
| Trovò, MG | 1 |
| Siffert, J | 1 |
| Velasquez, L | 1 |
| Allen, JC | 1 |
| Winter, S | 1 |
| Hung, CF | 1 |
| Bauman, GS | 1 |
| Wara, W | 1 |
| Davis, R | 1 |
| Edwards, M | 1 |
| Malec, M | 1 |
| Röhn, TA | 1 |
| Wagenknecht, B | 1 |
| Roth, W | 1 |
| Naumann, U | 1 |
| Gulbins, E | 1 |
| Krammer, PH | 1 |
| Walczak, H | 1 |
| Kochi, M | 1 |
| Ushio, Y | 1 |
| Walker, MD | 5 |
| Gutin, P | 1 |
| Boldrey, EB | 1 |
| Drafts, D | 1 |
| Enot, KJ | 1 |
| Ertel, IJ | 1 |
| Boesel, C | 1 |
| Heiss, WD | 1 |
| Turnheim, M | 1 |
| Mamoli, B | 1 |
| Paillas, JE | 2 |
| Prince, MA | 1 |
| Hassoun, J | 1 |
| Pellet, W | 2 |
| Peragut, JC | 1 |
| Pouillart, P | 6 |
| Mathé, G | 3 |
| Palangie, T | 2 |
| Lheritier, J | 3 |
| Huguenin, P | 4 |
| Gautier, H | 3 |
| Morin, P | 4 |
| Parrot, R | 3 |
| Garrett, MJ | 2 |
| Hughes, HJ | 2 |
| Freedman, LS | 1 |
| Buge, A | 3 |
| Schulz, U | 1 |
| Lapukins, Z | 1 |
| Seiler, RW | 1 |
| Baldini, M | 1 |
| Princi, L | 1 |
| Gutjahr, P | 1 |
| Dieterich, E | 1 |
| Tamura, M | 1 |
| Oster, MW | 1 |
| Hauw, JJ | 1 |
| Bataini, JP | 1 |
| Mashaly, R | 1 |
| Pertuiset, BF | 1 |
| Metzger, J | 1 |
| Gutin, PH | 6 |
| Hilton, J | 3 |
| Fumagalli, R | 2 |
| Weiss, JF | 1 |
| Pezzotta, S | 2 |
| Maker, HS | 3 |
| Syed, HH | 2 |
| Lehrer, GM | 3 |
| Waldbaur, H | 1 |
| Kuschnir, H | 1 |
| Engelmann, U | 1 |
| Schmidt, H | 1 |
| Schmack, B | 1 |
| Loubrieu, G | 1 |
| Elie, A | 1 |
| Ribadeau Dumas, JL | 1 |
| Pollet, JF | 1 |
| D'Estienne d'Orves, JF | 1 |
| Thy, HT | 1 |
| Ommaya, AK | 1 |
| Tator, CH | 1 |
| Day, A | 1 |
| Ng, R | 1 |
| Liberman, L | 1 |
| Fein, VJ | 1 |
| Allan, AE | 1 |
| Rottman, A | 1 |
| Brisman, R | 1 |
| Housepian, EM | 1 |
| Chang, C | 1 |
| Duffy, P | 1 |
| Balis, E | 1 |
| Racca, AR | 1 |
| Young, DF | 1 |
| Syed, H | 1 |
| Whetsell, W | 1 |
| Thy, TH | 1 |
| Gauthier, H | 1 |
| Ryall, RD | 1 |
| Jeremic, B | 1 |
| Jovanovic, D | 1 |
| Djuric, LJ | 1 |
| Jevremovic, S | 1 |
| Mijatovic, LJ | 1 |
| Sneed, PK | 2 |
| Phillips, TL | 2 |
| Weaver, KA | 2 |
| Larson, DA | 2 |
| Pyrich, M | 2 |
| Gościński, I | 3 |
| Krzyszkowski, T | 2 |
| Hildebrand, JG | 1 |
| Leibel, SA | 1 |
| Silver, P | 3 |
| Ogilvy-Stuart, AL | 1 |
| Shalet, SM | 1 |
| Gattamaneni, HR | 1 |
| Hannigan, J | 1 |
| Bradford, R | 1 |
| Sier, N | 1 |
| Trojanowski, T | 3 |
| Turowski, K | 3 |
| Peszyński, J | 3 |
| Koźniewska, H | 1 |
| Gaetani, P | 1 |
| Assietti, R | 1 |
| Markiewicz, P | 1 |
| Bielawski, A | 2 |
| Bendarzewska, B | 1 |
| Szymona, J | 1 |
| Dabrowska, A | 1 |
| Lopatkiewicz, J | 1 |
| Schold, SC | 1 |
| Djang, WT | 1 |
| Kurtzberg, J | 1 |
| Longee, DC | 1 |
| Halperin, EC | 1 |
| Falletta, JM | 1 |
| Coleman, RE | 1 |
| Oakes, WJ | 1 |
| McDermott, M | 1 |
| Krouwer, D | 1 |
| Wilson, C | 1 |
| Evans, CG | 1 |
| Bodell, WJ | 1 |
| Tokuda, K | 1 |
| Doane-Setzer, P | 1 |
| Smith, MT | 1 |
| Kapp, JP | 1 |
| Vance, RB | 1 |
| Resser, KJ | 1 |
| Yatsko, K | 1 |
| Nutik, S | 1 |
| Müller, H | 1 |
| Brock, M | 1 |
| Ernst, H | 1 |
| Fulton, DS | 1 |
| Urtasun, RC | 1 |
| McKinnon, S | 1 |
| Tanasichuk, H | 1 |
| Kamiński, S | 1 |
| Reinfus, M | 1 |
| Leszczyk, C | 1 |
| Lefkowitz, IB | 1 |
| Sutton, LN | 1 |
| Siegel, KR | 1 |
| Bruce, DA | 1 |
| Evans, AE | 1 |
| Schut, L | 1 |
| Rodriguez, LA | 1 |
| Fulton, D | 1 |
| Levin, V | 1 |
| Albers, GW | 1 |
| Hoyt, WF | 1 |
| Forno, LS | 1 |
| Shratter, LA | 1 |
| Chastagner, P | 1 |
| Olive, D | 1 |
| Philip, T | 1 |
| Zucker, JM | 1 |
| Czorny, A | 1 |
| Lapras, C | 1 |
| Brunat-Mentigny, M | 1 |
| McKenney, SA | 1 |
| Fehir, KM | 1 |
| Afra, D | 1 |
| Kocsis, B | 1 |
| Kerpel-Fronius, S | 1 |
| Eckhardt, S | 1 |
| Lee, FY | 1 |
| Workman, P | 1 |
| Roberts, JT | 1 |
| Bleehen, NM | 1 |
| Paul, EA | 1 |
| Mott, TJ | 1 |
| Godlee, JN | 1 |
| Tobias, JS | 1 |
| Capra, LG | 1 |
| Collins, CD | 1 |
| Mooney, C | 1 |
| Bozek, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma[NCT02414165] | Phase 2/Phase 3 | 403 participants (Actual) | Interventional | 2015-11-30 | Terminated (stopped due to Sponsor Decision) | ||
| A Randomized Phase 3 Open Label Study of Nivolumab Versus Bevacizumab and Multiple Phase 1 Safety Cohorts of Nivolumab or Nivolumab in Combination With Ipilimumab Across Different Lines of Glioblastoma[NCT02017717] | Phase 3 | 529 participants (Actual) | Interventional | 2014-02-07 | Active, not recruiting | ||
| A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma[NCT00003375] | Phase 2/Phase 3 | 370 participants (Actual) | Interventional | 1998-10-31 | Completed | ||
| A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV[NCT00052455] | Phase 3 | 500 participants (Anticipated) | Interventional | 2002-10-31 | Completed | ||
| Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old[NCT00002944] | Phase 3 | 428 participants (Actual) | Interventional | 1997-04-30 | Completed | ||
| A Prospective Cohort to Study the Effect of Postoperative Upfront Temozolomide Chemotherapy on IDH Mutational Low Grade Gliomas in Eloquent Areas[NCT02209428] | Phase 2 | 54 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
| PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA[NCT00002840] | Phase 3 | 350 participants (Anticipated) | Interventional | 1996-08-31 | Completed | ||
| A Phase I Study of Temozolomide and CCNU in Pediatric Patients With Newly Diagnosed Incompletely Resected Non-Brainstem High-Grade Gliomas[NCT00006024] | Phase 1 | 32 participants (Actual) | Interventional | 2000-11-30 | Completed | ||
| Does Varenicline Influence Alcohol Consumption in Alcohol Dependent Individuals?[NCT00846859] | Phase 2 | 162 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas[NCT01837862] | Phase 1/Phase 2 | 36 participants (Anticipated) | Interventional | 2013-10-22 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"ORR was measured by the percentage of participants whose best overall response (BOR) is confirmed Complete Response (CR) or Partial Response (PR) divided by response evaluable participants. The best overall response (BOR) is determined once all the data for the participant is known. BOR is defined as the best response designation, as determined by investigators, recorded between the date of randomization and the date of objectively documented progression per RANO criteria, the date of subsequent therapy, or date of surgical resection, whichever occurs first.~Confidence interval based on the Clopper and Pearson method. For the comparison of the odds ratio of Nivolumab over Bevacizumab, the Cochran-Mantel-Haenszel (CMH) method of weighting was utilized." (NCT02017717)
Timeframe: Time from randomization to the date of the first documented tumor progression or death due to any cause (up to approximately 31 months)
| Intervention | Percentage of participants (Number) |
|---|---|
| Cohort 2: Arm N3 | 7.8 |
| Cohort 2: Arm B | 23.1 |
OS(12) is measured as the percentage of participants alive at 12 months per Kaplan-Meier curve of OS. Z test with variance estimation based on Greenwood formula using log(-log) transformation. (NCT02017717)
Timeframe: From randomization to 12 months following randomization
| Intervention | Percentage of Participants (Number) |
|---|---|
| Cohort 2: Arm N3 | 41.8 |
| Cohort 2: Arm B | 42.4 |
"OS was measured in months from the time of randomization to the event date (death) due to any cause. A participant who has not died will be censored at the last known alive date.~Based on Kaplan-Meier Estimates. Hazard ratio from Cox proportional hazard model stratified by presence of measurable lesions at baseline per IVRS. P-value from log-rank test stratified by presence of measurable lesions at baseline per IVRS." (NCT02017717)
Timeframe: Time between the date of randomization and the date of death due to any cause (up to 17Jun2019, approximately 5 years)
| Intervention | Months (Median) |
|---|---|
| Cohort 2: Arm N3 | 9.77 |
| Cohort 2: Arm B | 10.05 |
"OS was measured in months from the time of randomization (Part B) or time of treatment (Part A) to the event date (death) due to any cause. A participant who has not died will be censored at the last known alive date.~Based on Kaplan-Meier Estimates." (NCT02017717)
Timeframe: Time between the date of randomization and the date of death due to any cause (up to 17Jun2019, approximately 5 years)
| Intervention | Months (Median) |
|---|---|
| Part A Cohort 1c: Arm N3+RT+TMZ | 22.08 |
| Part A Cohort 1d: Arm N3+RT | 14.41 |
| Part B Cohort 1c: Arm N3+RT+TMZ | 15.95 |
| Part B Cohort 1d: Arm N3+RT | 13.96 |
PFS was measured in months from the time of randomization to the date of the first documented tumor progression or death due to any cause. Based on Kaplan-Meier Estimates. Hazard ratio from Cox proportional hazard model stratified by presence of measurable lesions at baseline per IVRS. (NCT02017717)
Timeframe: Time from randomization to the date of the first documented tumor progression or death due to any cause (up to 17Jun2019, approximately 5 years)
| Intervention | Months (Median) |
|---|---|
| Cohort 2: Arm N3 | 1.51 |
| Cohort 2: Arm B | 3.61 |
The percentage of participants who experienced an adverse event by worst grade in each treatment arm. Toxicities were graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. MedDRA Version: 24.1 (NCT02017717)
Timeframe: From first dose to 30 days post last dose (up to approximately 34 months).
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | |
| Cohort 1: Arm N1+I3 | 0 | 10.0 | 70.0 | 20.0 | 0 |
| Cohort 1: Arm N3 | 20.0 | 30.0 | 40.0 | 10.0 | 0 |
| Cohort 1b: Arm N3+I1 | 5.0 | 25.0 | 50.0 | 20.0 | 0 |
| Part A Cohort 1c: Arm N3+RT+TMZ | 6.5 | 12.9 | 58.1 | 22.6 | 0 |
| Part A Cohort 1d: Arm N3+RT | 13.3 | 26.7 | 33.3 | 20.0 | 3.3 |
| Part B Cohort 1c: Arm N3+RT+TMZ | 3.6 | 28.6 | 50.0 | 10.7 | 3.6 |
| Part B Cohort 1d: Arm N3+RT | 17.9 | 25.0 | 35.7 | 21.4 | 0 |
The percentage of participants who experienced a drug-related adverse event leading to drug discontinuation by worst grade (grade 5 being the worst) prior to complete four-dose treatment. Toxicities were graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. MedDRA Version: 24.1 (NCT02017717)
Timeframe: Includes events reported between first dose and 30 days after last dose of study therapy (up to 3 doses, up to approximately 2 months)
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | |
| Cohort 1: Arm N1+I3 | 0 | 0 | 16.7 | 33.3 | 0 |
| Cohort 1: Arm N3 | 0 | 0 | 0 | 0 | 0 |
| Cohort 1b: Arm N3+I1 | 0 | 0 | 0 | 0 | 0 |
| Part A Cohort 1c: Arm N3+RT+TMZ | 0 | 0 | 66.7 | 0 | 0 |
| Part A Cohort 1d: Arm N3+RT | 0 | 0 | 0 | 0 | 0 |
| Part B Cohort 1c: Arm N3+RT+TMZ | 0 | 0 | 0 | 0 | 0 |
| Part B Cohort 1d: Arm N3+RT | 0 | 0 | 50.0 | 0 | 0 |
The percentage of participants who experienced a serious adverse event by worst grade in each treatment arm. Toxicities were graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. MedDRA Version: 24.1 (NCT02017717)
Timeframe: From first dose to 30 days post last dose (up to approximately 34 months).
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | |
| Cohort 1: Arm N1+I3 | 0 | 0 | 60.0 | 20.0 | 0 |
| Cohort 1: Arm N3 | 0 | 10.0 | 40.0 | 0 | 0 |
| Cohort 1b: Arm N3+I1 | 0 | 5.0 | 35.0 | 15.0 | 0 |
| Part A Cohort 1c: Arm N3+RT+TMZ | 3.2 | 0 | 45.2 | 16.1 | 0 |
| Part A Cohort 1d: Arm N3+RT | 0 | 16.7 | 16.7 | 16.7 | 3.3 |
| Part B Cohort 1c: Arm N3+RT+TMZ | 0 | 3.6 | 35.7 | 3.6 | 3.6 |
| Part B Cohort 1d: Arm N3+RT | 0 | 10.7 | 32.1 | 14.3 | 0 |
"The percentage of participants who experienced a laboratory abnormality of the liver in each treatment arm.~MedDRA Version: 24.1~Aspartate aminotransferase (AST) Alanine aminotransferase (ALT) Upper Limit of Normal (ULN) Denominator corresponds to participants with at least on one treatment measurement of the corresponding laboratory parameter. Includes laboratory results reported after the first dose and within 30 days of last dose of study therapy." (NCT02017717)
Timeframe: From first dose to 30 days post last dose (up to approximately 34 months).
| Intervention | Percentage of participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ALT OR AST > 3*ULN | ALT OR AST > 5*ULN | ALT OR AST > 10*ULN | ALT OR AST > 20*ULN | TOTAL BILIRUBIN (Tbili) > 2*ULN | ALP > 1.5*ULN | ALT or AST > 3xULN w/ Tbili > 1.5*ULN within 1 day | ALT or AST > 3*ULN w/ Tbili > 1.5*ULN within 30 days | ALT or AST > 3xULN w/ Tbili > 2*ULN within 1 day | ALT or AST > 3*ULN w/ Tbili > 2*ULN within 30 days | |
| Cohort 1: Arm N1+I3 | 30.0 | 20.0 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 |
| Cohort 1: Arm N3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 10.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cohort 1b: Arm N3+I1 | 15.8 | 10.5 | 5.3 | 5.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Part A Cohort 1c: Arm N3+RT+TMZ | 22.6 | 12.9 | 6.5 | 3.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Part A Cohort 1d: Arm N3+RT | 10.0 | 3.3 | 3.3 | 3.3 | 0.0 | 3.3 | 0.0 | 0.0 | 0.0 | 0.0 |
| Part B Cohort 1c: Arm N3+RT+TMZ | 18.5 | 11.1 | 3.7 | 0.0 | 7.4 | 0.0 | 3.7 | 3.7 | 3.7 | 3.7 |
| Part B Cohort 1d: Arm N3+RT | 14.8 | 3.7 | 3.7 | 3.7 | 0.0 | 3.7 | 0.0 | 0.0 | 0.0 | 0.0 |
"The percentage of participants who experienced a laboratory abnormality of the thyroid in each treatment arm.~MedDRA Version: 24.1~Free T3 (FT3) Free T4 (FT4) Lower Limit of Normal (LLN)~(A) Within a 2-week window after the abnormal TSH test date. (B) Includes participants with TSH abnormality and with no FT3/FT4 test values in the 2-week window or with non-abnormal value(s) from only one of the two tests and no value from the other test." (NCT02017717)
Timeframe: From first dose to 30 days post last dose (up to approximately 34 months).
| Intervention | Percentage of participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| TSH > ULN | TSH > ULN, WITH TSH <= ULN AT BASELINE | TSH > ULN, WITH AT LEAST ONE FT3/FT4 TEST < LLN | TSH > ULN, WITH ALL OTHER FT3/FT4 TEST >= LLN | TSH > ULN, WITH FT3/FT4 TEST MISSING | TSH < LLN | TSH < LLN, WITH TSH >= LLN AT BASELINE | TSH | TSH < LLN, WITH ALL OTHER FT3/FT4 TEST <= ULN | TSH < LLN, WITH FT3/FT4 TEST MISSING | |
| Cohort 1: Arm N1+I3 | 20.0 | 20.0 | 20.0 | 0.0 | 0.0 | 60.0 | 60.0 | 30.0 | 20.0 | 10.0 |
| Cohort 1: Arm N3 | 50.0 | 30.0 | 30.0 | 10.0 | 10.0 | 30.0 | 30.0 | 10.0 | 20.0 | 0.0 |
| Cohort 1b: Arm N3+I1 | 10.5 | 10.5 | 10.5 | 0.0 | 0.0 | 31.6 | 31.6 | 15.8 | 10.5 | 5.3 |
| Part A Cohort 1c: Arm N3+RT+TMZ | 23.3 | 20.0 | 13.3 | 6.7 | 3.3 | 43.3 | 33.3 | 10.0 | 30.0 | 3.3 |
| Part A Cohort 1d: Arm N3+RT | 16.7 | 16.7 | 13.3 | 0.0 | 3.3 | 40.0 | 40.0 | 13.3 | 16.7 | 10.0 |
| Part B Cohort 1c: Arm N3+RT+TMZ | 11.1 | 11.1 | 7.4 | 3.7 | 0.0 | 22.2 | 18.5 | 11.1 | 11.1 | 0.0 |
| Part B Cohort 1d: Arm N3+RT | 7.4 | 7.4 | 0.0 | 7.4 | 0.0 | 33.3 | 18.5 | 0.0 | 29.6 | 3.7 |
23 reviews available for lomustine and Glial Cell Tumors
| Article | Year |
|---|---|
Novel "T-Dimension" Therapies for Pediatric Optic Pathway Glioma: A Timely, Targeted, and Tailored Treatment Trend.
Topics: Child; Combined Modality Therapy; Glioma; Humans; Lomustine; Radiosurgery; Vincristine | 2022 |
Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; | 2020 |
Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytarabine; Dacarbazine; Dis | 2017 |
[Management of gliomas].
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Co | 2014 |
Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma.
Topics: Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Clinical Trials, Phase III as T | 2014 |
Low-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; | 2015 |
Nitrosoureas in the Management of Malignant Gliomas.
Topics: Dacarbazine; Glioma; Humans; Lomustine; Nitrosourea Compounds; Organophosphorus Compounds; Procarbaz | 2016 |
Procarbazine--a traditional drug in the treatment of malignant gliomas.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cli | 2008 |
What is the translational efficacy of chemotherapeutic drug research in neuro-oncology? A systematic review and meta-analysis of the efficacy of BCNU and CCNU in animal models of glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Disease Models, Animal; Drug Evaluation; Gli | 2009 |
Chemotherapy for diffuse low-grade gliomas in adults.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chemother | 2011 |
Chemotherapy in low-grade gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Clinical Trials | 2012 |
Integrated phase II/III clinical trials in oncology: a case study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2012 |
Conformal irradiation for pure and mixed oligodendroglioma: the experience of Centre Leon Berard Lyon.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Damage, Chronic; Brain Injuries | 2003 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms | 2004 |
[Clinical significance of mustoforan in management of malignant glioma].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Blood-Brain Barr | 2007 |
High dose chemotherapy with autologous bone marrow rescue for high grade gliomas of the brain: a potential for improvement in therapeutic results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brain Neoplasms; Carmus | 1984 |
Treatment of neuroectodermal brain tumors.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; | 1982 |
Aggressive oligodendroglioma: a chemosensitive tumor.
Topics: Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Ad | 1994 |
Acute leukemia following treatment of malignant glioma.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Fatal Outcome | 1998 |
Multidisciplinary management of adult anaplastic oligodendrogliomas and anaplastic mixed oligo-astrocytomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; G | 2001 |
[Chemo-radiotherapy for malignant brain tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Central Nervous System | 2002 |
Immunotherapy of gliomas: a review.
Topics: Adult; Animals; Azaguanine; BCG Vaccine; Brain; Brain Neoplasms; Child; Disease Models, Animal; Glio | 1976 |
Chemotherapy: the agents in current use.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; Drug Therapy, Combination; Glioma; | 1975 |
46 trials available for lomustine and Glial Cell Tumors
| Article | Year |
|---|---|
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neop | 2020 |
Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy, Adjuvant; | 2014 |
Upfront chemotherapy with CCNU alone for adults' low-grade gliomas: a clinical analysis.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease-Free Survival; Female | 2014 |
Patients with primary brain tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Che | 2014 |
Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial.
Topics: Antineoplastic Agents; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dac | 2014 |
Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2015 |
Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chil | 2016 |
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2009 |
Phase II TPDCV protocol for pediatric low-grade hypothalamic/chiasmatic gliomas: 15-year update.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Di | 2010 |
Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chi-Square | 2010 |
Feasibility and efficacy of repeated chemotherapy for progressive pediatric low-grade gliomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Di | 2011 |
Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Central Nervous System | 2012 |
Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemorad | 2012 |
Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC stu
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemothera | 2013 |
Tolerance of nitrosurea-based multiagent chemotherapy regime for low-grade pediatric gliomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Child; Chi | 2003 |
Outcome of children with centrally reviewed low-grade gliomas treated with chemotherapy with or without radiotherapy on Children's Cancer Group high-grade glioma study CCG-945.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Pr | 2003 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms | 2004 |
Phase I study of temozolomide and lomustine in the treatment of high grade malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2006 |
A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2008 |
[Combined treatment of malignant gliomas].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cobalt Radioisotopes; Drug Therapy, Com | 1983 |
Treatment of neuroectodermal brain tumors.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; | 1982 |
Evaluation of CCNU, VM-26 plus CCNU, and procarbazine in supratentorial brain gliomas. Final evaluation of a randomized study. European Organization for Research on Treatment of Cancer (EORTC) Brain Tumor Group.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Drug Therapy, Combination; Female; | 1981 |
Primary intracranial gliomas: clinical studies and treatment regimens of the Brain Tumor Research Center, University of California, San Francisco, 1977-1979.
Topics: Antineoplastic Agents; Brain Neoplasms; California; Carmustine; Clinical Trials as Topic; Drug Thera | 1981 |
A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study.
Topics: Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Female; Glioma; Humans; Lomustine; Male; Mi | 1993 |
Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool | 1997 |
Synchronous radiochemotherapy in unfavorable brain tumors of children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Che | 1998 |
Dose-intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Pr | 1998 |
Phase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine chemotherapy with radiotherapy for treating malignant glioma in children.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Pr | 2000 |
Chemotherapy: adjuvant to surgery and radiation therapy.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Fluorouracil; Glioma; | 1975 |
Treatment of malignant gliomas and brain metastases in adults using a combination of adriamycine, VM 26, and CCNU. Results of a type II trial.
Topics: Adult; Aged; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Therapy, | 1977 |
A comparison of radiotherapy alone with radiotherapy and CCNU in cerebral glioma.
Topics: Adult; Age Factors; Aged; Brain Neoplasms; Clinical Trials as Topic; Evaluation Studies as Topic; Fe | 1978 |
Effect of CCNU on survival rate of objective remission and duration of free interval in patients with malignant brain glioma--final evaluation. E.O.R.T.C. Brain Tumor Group.
Topics: Brain Neoplasms; Clinical Trials as Topic; Female; Glioma; Humans; Lomustine; Male; Neoplasm Recurre | 1978 |
[A study of the use of sequential chemotherapy in 176 cases of glioblastoma (author's transl)].
Topics: Adult; Brain Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Therapy, Combination; Follow-Up | 1978 |
[Combined postoperative therapy of glial brain tumors. Initial results of the pilot study].
Topics: Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Cobalt Radioisotopes; Glioma; Humans; Lomust | 1978 |
[Letter: Chemotherapy of operated malignant brain gliomas using a combination of VM 26 and CCNU].
Topics: Brain Neoplasms; Clinical Trials as Topic; Drug Therapy, Combination; Follow-Up Studies; Glioma; Hum | 1976 |
[Trial treatment of glioblastomas in adults and cerebral metastais by adriamycin, VM 26 and CCNU combination. Result of a type II trial].
Topics: Adult; Aged; Brain Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Evaluation; Drug Therapy, | 1976 |
Adjuvant nitrosourea therapy for glioblastoma.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Child; Child, Preschool; Drug Evaluation; Fema | 1976 |
Effect of CCNU on survival, rate of objective remission and duration of free interval in patients with malignant brain glioma--first evaluation.
Topics: Brain Neoplasms; Dexamethasone; Glioma; Humans; Lomustine; Neoplasm Recurrence, Local; Nitrosourea C | 1976 |
Advantage of post-radiotherapy chemotherapy with CCNU, procarbazine, and vincristine (mPCV) over chemotherapy with VM-26 and CCNU for malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined | 1992 |
[Chemotherapy of malignant glioma. Results of studies of the EORTC group of brain tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Modality Therap | 1992 |
External irradiation followed by an interstitial high activity iodine-125 implant "boost" in the initial treatment of malignant gliomas: NCOG study 6G-82-2.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Brain Neoplasms; Combine | 1991 |
Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 1990 |
Quality of survival of patients with brain gliomas treated with postoperative CCNU and radiation therapy.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Disab | 1989 |
Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; C | 1985 |
Long-term survival and recurrence-free interval in combined surgical, radio- and chemotherapy of malignant brain gliomas.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Child; Child, Preschool; Clinical Trials as Topic; Combine | 1985 |
Postoperative radiotherapy and radiotherapy combined with CCNU chemotherapy for treatment of brain gliomas.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Clinical Trials as Topic; Female; Glioma; Humans; Lomustin | 1988 |
107 other studies available for lomustine and Glial Cell Tumors
| Article | Year |
|---|---|
Lomustine Incorporated Lipid Nanostructures Demonstrated Preferential Anticancer Properties in C6 Glioma Cell Lines with Enhanced Pharmacokinetic Profile in Mice.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Brain; Cell Line, Tumor; Cell Survival; Dru | 2021 |
Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET.
Topics: Adult; Brain Neoplasms; Glioma; Humans; Lomustine; Magnetic Resonance Imaging; Positron-Emission Tom | 2023 |
Triple combination of lomustine, temozolomide and irradiation reduces canine glioma cell survival in vitro.
Topics: Animals; Cell Survival; Dacarbazine; Dog Diseases; Dogs; Glioma; Lomustine; Temozolomide | 2023 |
[Oligodendroglioma, IDH Mutation and 1p/19q Codeletion].
Topics: Cognition; Glioma; Humans; Lomustine; Mutation; Oligodendroglioma | 2023 |
Salvage chemotherapy after failure of targeted therapy in a child with BRAF V600E low-grade glioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child, Preschool; Glioma; Humans; L | 2021 |
A comparative study of the effectiveness and safety of combined procarbazine, lomustine, and vincristine as a therapeutic method for recurrent high-grade glioma: A protocol for systematic review and meta-analysis.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Glioma; Humans; | 2020 |
One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Drug-Related Side Effects an | 2021 |
Cost-effectiveness of radiation and chemotherapy for high-risk low-grade glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Cost-Bene | 2017 |
Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2018 |
Survival times in dogs with presumptive intracranial gliomas treated with oral lomustine: A comparative retrospective study (2008-2017).
Topics: Administration, Oral; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dog Diseases; Dog | 2018 |
Drug development for glioma: are we repeating the same mistakes?
Topics: Drug Development; Glioblastoma; Glioma; Humans; Lomustine; Phenylurea Compounds; Pyridines | 2019 |
Prophylactic use of pegfilgrastim in patients treated with a nitrosourea and teniposide for recurrent glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Communicable Diseases; Disease-Free Sur | 2014 |
Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2015 |
Kinetic evaluation of low-grade gliomas in adults before and after treatment with CCNU alone.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy | 2015 |
Increasing the Time Interval between PCV Chemotherapy Cycles as a Strategy to Improve Duration of Response in Low-Grade Gliomas: Results from a Model-Based Clinical Trial Simulation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Protocols; Clinical | 2015 |
Nitrosoureas inhibit the stathmin-mediated migration and invasion of malignant glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Movement; Glioma; Lomustine; Mice; | 2008 |
In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytes; Carb | 2008 |
Low-grade glioma: a challenge in therapeutic options: the role of radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2008 |
Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2009 |
Bevacizumab is active as a single agent against recurrent malignant gliomas.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Glioma; Humans; Lomustine; | 2010 |
HPLC method validation for the quantification of lomustine to study pharmacokinetics of thermosensitive liposome-encapsulated lomustine containing iohexol for CT imaging in C6 glioma rats.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Brain Neoplasms; Calibration; Cell Line, Tumor; Ch | 2011 |
Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Femal | 2002 |
Interobserver variability in the radiological assessment of response to chemotherapy in glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplat | 2003 |
[Suppression of nitric oxide on cytotoxicity of Lomustine in glioma cell line BT- 325].
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioma; Humans; Inte | 2003 |
Intrinsic brainstem choroid plexus papilloma. Case report.
Topics: Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Choroid Plexus Neoplasms; Female; Glioma; H | 2004 |
Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; British Columbia | 2006 |
Radiotherapy plus concurrent and adjuvant procarbazine, lomustine, and vincristine chemotherapy for patients with malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemothera | 2007 |
Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; | 2008 |
Cryptococcal meningitis in patients with glioma: a report of two cases.
Topics: Adult; Aged; Amphotericin B; Anti-Inflammatory Agents; Antifungal Agents; Antineoplastic Agents, Alk | 2008 |
5-Fluorouracil and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) followed by hydroxyurea, misonidazole, and irradiation for brain stem gliomas: a pilot study of the Brain Tumor Research Center and the Childrens Cancer Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Bra | 1984 |
Multimodality treatment of malignant gliomas. Comparison of several adjuvant approaches.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Drug Therapy, Combination; Ependymoma; Glioblastoma; | 1981 |
Clinical toxicity of combined modality treatment with nitrosourea derivatives for central nervous system tumors.
Topics: Bone Marrow Diseases; Brain Neoplasms; Carmustine; Gastrointestinal Diseases; Glioblastoma; Glioma; | 1982 |
[Antimitotic chemotherapy of supratentorial cerebral glioma in adults. Apropos of 56 cases].
Topics: Adult; Aged; Brain Neoplasms; Drug Therapy, Combination; Female; Glioma; Humans; Lomustine; Male; Mi | 1983 |
[Prognostic value of gliofibrillary protein assay in malignant gliomas treated with chemo- and radiotherapy].
Topics: Adolescent; Adult; Brain Neoplasms; Drug Therapy, Combination; Female; Follow-Up Studies; Glial Fibr | 1983 |
Megadose chemotherapy with bone marrow rescue.
Topics: Animals; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma | 1984 |
Treatment of brain giomas with high dose of CCNU and autologous bone marrow transplantation.
Topics: Bone Marrow Transplantation; Brain Neoplasms; Glioma; Hematologic Diseases; Humans; Lomustine; Nitro | 1980 |
Proper analysis of clinical trials for malignant glioma.
Topics: Carmustine; Glioma; Humans; Lomustine; Methods; Statistics as Topic | 1982 |
[The effects of combined chemotherapy (adriamycin/VM/26/CCNU) in brian tumours in adults and animal experiments (author's transl)].
Topics: Adult; Aged; Animals; Brain Neoplasms; Doxorubicin; Drug Therapy, Combination; Ethylnitrosourea; Fem | 1982 |
[Analysis of long-term effects of CCNU on gliomas of the brain].
Topics: Adolescent; Adult; Brain Neoplasms; Child; Female; Glioma; Humans; Lomustine; Male; Middle Aged; Nit | 1982 |
[Results of combined modality treatment of malignant gliomas. Comparison of postoperative irradiation, chemotherapy, and combined radio-polychemotherapy (author's transl)].
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Therapy, Combination; Female; Glioma; Huma | 1981 |
The effect of topical CCNU(1-(2-chloroethyl)-3 cyclohexyl 1 nitrosurea) treatment on lipid peroxidation of glial tumours transplanted on rat brain.
Topics: Administration, Topical; Animals; Brain; Brain Neoplasms; Glioma; Injections, Intralesional; Lipid P | 1995 |
Assay of anticancer drugs in tissue culture: comparison of a tetrazolium-based assay and a protein binding dye assay in short-term cultures derived from human malignant glioma.
Topics: Antineoplastic Agents; Coloring Agents; Drug Screening Assays, Antitumor; Glioma; Humans; Lomustine; | 1996 |
Quantitative DNA analysis of an intracerebrally transplanted brain tumour model after experimental chemotherapy with BCNU and CCNU.
Topics: Animals; Brain Neoplasms; Brain Tissue Transplantation; Carmustine; Cell Division; Cytophotometry; D | 1995 |
Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Pr | 1996 |
Retreatment of patients with intracranial gliomas by external beam radiotherapy and cytotoxic chemotherapy.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Case-Control Studies; Child; Combined Modality Therap | 1997 |
Pretreatment prediction of the chemotherapeutic response of human glioma cell cultures using nuclear magnetic resonance spectroscopy and artificial neural networks.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Drug Resistance, Neoplasm; Drug S | 1997 |
[Assessment of procarbazine, vincristine and lomustine association (PCV protocol) in oligodendroglioma and mixed glioma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Gl | 1997 |
Neurotoxicity of combination chemotherapy with procarbazine, CCNU and vincristine (PCV) for recurrent glioma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 1998 |
Reirradiation and lomustine in patients with relapsed high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Disease | 1999 |
Dose-intensive, time-compressed procarbazine, CCNU, vincristine (PCV) with peripheral blood stem cell support and concurrent radiation in patients with newly diagnosed high-grade gliomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dose-Res | 1999 |
Poly(ADP-ribose) polymerase-independent potentiation of nitrosourea cytotoxicity by 3-aminobenzamide in human malignant glioma cells.
Topics: Benzamides; Binding Sites; Carmustine; Cell Survival; Dose-Response Relationship, Drug; Drug Synergi | 2000 |
Effects of carmustine and lomustine on arylamine N-acetyltransferase activity and 2-aminofluorene-DNA adducts in rat glial tumor cells.
Topics: Animals; Arylamine N-Acetyltransferase; Brain Neoplasms; Carmustine; DNA Adducts; Fluorenes; Glioma; | 2000 |
CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Brai | 2001 |
Single-agent chemotherapy of brain tumors. A five-year review.
Topics: Astrocytoma; Bone Marrow Diseases; Brain Neoplasms; Carmustine; Glioma; Humans; Imidazoles; Lomustin | 1976 |
Brain tumors in children.
Topics: Adolescent; Astrocytoma; Brain; Brain Neoplasms; Child; Diagnosis, Differential; Ependymoma; Female; | 1978 |
Combination chemotherapy of malignant glioma. Effect of postoperative treatment with CCNU, vincristine, amethopterine and procarbazine.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Drug Therapy, Combination; Glioma; Humans; Lomustine; Meth | 1978 |
[Value of chemotherapy associated with conventional treatment of malignant gliomas of the brain. Study of 95 cases with histological verification and follow-up of 1 to 6 years 9 months].
Topics: Administration, Oral; Adult; Brain Neoplasms; Carmustine; Drug Evaluation; Drug Therapy, Combination | 1979 |
Delayed response to brain tumor chemotherapy.
Topics: Adult; Brain Neoplasms; Glioma; Humans; Lomustine; Male; Middle Aged; Nitrosourea Compounds; Prednis | 1979 |
Treatment of primitive malignant tumors of the central nervous system. Clinical evaluation of 91 cases.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Ependymoma; Glioma; Humans; Lomustine; Oligodendroglioma | 1979 |
[Risk of a second malignant neoplasm after successful treatment of a malignant tumour in children (author's transl)].
Topics: Adolescent; Age Factors; Child; Child, Preschool; Craniopharyngioma; Diagnostic Errors; Female; Fibr | 1979 |
Brain tumor chemotherapy using a rat glioma model.
Topics: Animals; Bone Marrow; Brain Neoplasms; Cell Nucleus; Disease Models, Animal; Dose-Response Relations | 1979 |
Combination chemotherapy for extracranial metastases of a primary malignant cerebral neoplasm.
Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Cisplatin; Cyclophosphamide; Doxorubi | 1979 |
Malignant gliomas treated after surgery by combination chemotherapy and delayed radiation therapy. Part II. Tolerance to irradiation after chemotherapy.
Topics: Brain; Brain Neoplasms; Drug Therapy, Combination; Glioma; Humans; Lomustine; Neoplasm Recurrence, L | 1979 |
Experimental brain tumor chemotherapy: DNA damage in the rat gliosarcoma 9L treated with CCNU.
Topics: Animals; Brain Neoplasms; DNA, Neoplasm; DNA, Single-Stranded; Drug Evaluation, Preclinical; Glioma; | 1977 |
Desmosterol: a biochemical marker of glioma growth.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Cholesterol; Chromatography, Gas; Desmosterol; Diagnosis, | 1977 |
Effect of phospholipids on maintenance of the cytotoxicity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in aqueous suspension.
Topics: Cell Survival; Cells, Cultured; Glioma; Lomustine; Neoplasms, Experimental; Nitrosourea Compounds; P | 1978 |
Experiments on the chemotheraphy of a transplantable glioblastoma in the rat, employing 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).
Topics: Animals; Brain Neoplasms; Glioma; Lomustine; Male; Methylnitrosourea; Neoplasm Transplantation; Neop | 1978 |
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 44-1978.
Topics: Astrocytoma; Carcinoma, Squamous Cell; Ependymoma; Female; Glioma; Hemangioma, Cavernous; Humans; Li | 1978 |
The contemporary role of chemotherapy in the treatment of malignant brain tumor.
Topics: Adrenal Cortex Hormones; Animals; Brain Neoplasms; Carmustine; Dose-Response Relationship, Drug; Dru | 1978 |
[Neurogliale cerebral tumors: test of chemotherapy treatment. Forty five cases (author's transl)].
Topics: Adult; Aged; Brain Neoplasms; Child, Preschool; Drug Therapy, Combination; Echoencephalography; Elec | 1978 |
Correlations between experimental chemotherapy in the murine glioma and effectiveness of clinical therapy regimens.
Topics: Animals; Carmustine; Dianhydrogalactitol; Drug Therapy, Combination; Ellipticines; Glioma; Lomustine | 1978 |
Treatment of adult malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Administration Schedule; Drug Therapy, Com | 1978 |
Adjuvant chemotherapy in malignant brain gliomas.
Topics: Brain Neoplasms; Drug Administration Schedule; Glioma; Humans; Lomustine | 1978 |
Chemotherapy of an experimental glioma with nitrosoureas.
Topics: Animals; Brain Neoplasms; Drug Administration Schedule; Ependymoma; Female; Glioma; Injections; Inje | 1977 |
DNA damage in the intracerebral rat gliosarcoma 9L treated with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
Topics: Animals; Brain Neoplasms; Centrifugation, Density Gradient; DNA Repair; DNA, Neoplasm; DNA, Single-S | 1977 |
Environmental factors in glial tumor response to 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea: effect of cell confluence.
Topics: Cell Cycle; Cell Survival; Cells, Cultured; DNA, Neoplasm; Glioma; Lomustine; Neoplasms, Experimenta | 1977 |
Chemotherapy of brain tumors.
Topics: Brain Neoplasms; Carmustine; Drug Combinations; Glioma; Humans; Lomustine; Methotrexate; Podophyllot | 1976 |
Nitrosourea pharmacodynamics in relation to the central nervous system.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Glioma; Humans; Lomustine; Mice; Molecula | 1976 |
Nitrosourea chemotherapy for primary malignant gliomas.
Topics: Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorouracil; Glioma; Humans; Lomustine; Neo | 1976 |
Lomustine (CeeNU).
Topics: Brain Neoplasms; Glioma; Hodgkin Disease; Humans; Lomustine; Nitrosourea Compounds | 1976 |
Sterols in cerebrospinal fluid during nitrosourea chemotherapy of human brain tumors.
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Cholesterol; Desmosterol; Female; Glioma; Humans; I | 1976 |
Chemotherapy of malignant glioma with CCNU alone and CCNU combined with vincristine sulfate and procarbazine hydrochloride.
Topics: Brain Neoplasms; Drug Evaluation; Drug Therapy, Combination; Glioma; Humans; Lomustine; Nitrosourea | 1976 |
Environmental factors modifying the effect of CCNU on glioma in vitro and in vivo.
Topics: Animals; Brain Neoplasms; Cells, Cultured; Glioma; In Vitro Techniques; Lomustine; Mice; Nitrosourea | 1976 |
Treatment of malignant gliomas and brain metastases in adults with a combination of adriamycin, VM 26, and CCNU. Results of a phase II trail.
Topics: Adult; Aged; Brain Neoplasms; Doxorubicin; Drug Therapy, Combination; Drug Tolerance; Female; Glioma | 1976 |
CCNU in brain tumours.
Topics: Adolescent; Adult; Brain Neoplasms; Bronchial Neoplasms; Cerebellar Neoplasms; Child, Preschool; Fem | 1975 |
Brachytherapy of brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Brain Neoplasms; Child; Combined Moda | 1992 |
[Diagnosis and treatment of recurrent brain glioma].
Topics: Adult; Brain Neoplasms; Cobalt Radioisotopes; Female; Glioma; Humans; Lomustine; Male; Middle Aged; | 1992 |
Thyroid function after treatment of brain tumors in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine | 1991 |
The VM model of glioma: preparation of multicellular tumour spheroids (MTS) and their response to chemotherapy.
Topics: Animals; Carmustine; Cell Division; Disease Models, Animal; Drug Screening Assays, Antitumor; Glioma | 1990 |
Postoperative radiotherapy and radiotherapy combined with CCNU chemotherapy for treatment of brain gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Glioma; Humans; Lomustine | 1990 |
Chemotherapy for malignant gliomas of the brain: a review of ten-years experience.
Topics: Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Cyclohexenes; Glioma; | 1990 |
Criteria for termination of phase II chemotherapy for patients with progressive or recurrent brain tumor.
Topics: Adolescent; Antineoplastic Agents; Astrocytoma; Aziridines; Benzoquinones; Brain Neoplasms; Cohort S | 1989 |
Irradiation and CCNU in glioma therapy.
Topics: Brain Neoplasms; Combined Modality Therapy; Glioma; Humans; Lomustine | 1989 |
Glutathione and related enzymes in rat brain tumor cell resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea and nitrogen mustard.
Topics: Animals; Brain Neoplasms; Buthionine Sulfoximine; Carmustine; Cell Line; Cell Survival; Chromatograp | 1987 |
Supraophthalmic carotid infusion for recurrent glioma: rationale, technique, and preliminary results for cisplatin and BCNU.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Car | 1985 |
Misonidazole and CCNU chemotherapy for recurrent primary brain tumor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bone Marrow Diseases; Brain Neop | 1987 |
Results of the treatment of children with recurrent gliomas with lomustine and vincristine.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool | 1988 |
Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brain Stem; Chil | 1988 |
Treatment response in malignant optic glioma of adulthood.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bromodeoxyuridine; Cranial Nerve Neoplasms; F | 1988 |
[Efficacy of the "8 drugs in a day" protocol in brain tumors in children].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cer | 1988 |
Myelofibrosis following treatment with a nitrosourea for malignant glioma.
Topics: Brain Neoplasms; Glioma; Humans; Lomustine; Male; Middle Aged; Primary Myelofibrosis | 1986 |
Dibromodulcitol-based combined postoperative chemotherapy of malignant astrocytomas and glioblastomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined | 1986 |
Clinical pharmacokinetics of oral CCNU (lomustine).
Topics: Administration, Oral; Adult; Biopsy; Cecal Neoplasms; Cell Line; Chromatography, High Pressure Liqui | 1985 |
Assay of anti-cancer drugs in tissue culture: relationship of relapse free interval (RFI) and in vitro chemosensitivity in patients with malignant cerebral glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cells, Cultured; Female; Gli | 1985 |
Chemosensitivity testing in the treatment of malignant gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Glioma; Humans; Lomustine; Procarba | 1985 |